Loading...
SNCE logo

Science 37 Holdings, Inc.NasdaqCM:SNCE Stock Report

Market Cap US$34.7m
Share Price
n/a
My Fair Value
n/a
1Y30.9%
7D0.3%
1D
Portfolio Value
​
View

Science 37 Holdings, Inc.

NasdaqCM:SNCE Stock Report

Market Cap: US$34.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Science 37 Holdings (SNCE) Stock Overview

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. More details

SNCE fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 91.4% below our estimate of its fair value

Revenue is forecast to grow 17.47% per year

Trading at good value compared to peers and industry

Risk Analysis

Does not have a meaningful market cap ($35M)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Has less than 1 year of cash runway

+ 1 more risk

SNCE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Science 37 Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Science 37 Holdings
Historical stock prices
Current Share PriceUS$5.75
52 Week HighUS$12.96
52 Week LowUS$3.73
Beta0.57
1 Month Change1.23%
3 Month Change30.39%
1 Year Change30.86%
3 Year Change-97.22%
5 Year Changen/a
Change since IPO-97.14%

Recent News & Updates

Recent updates

Analysis Article • Dec 18

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

With a price-to-sales (or "P/S") ratio of 0.5x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) may be sending very bullish...
Analysis Article • Apr 17

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

You may think that with a price-to-sales (or "P/S") ratio of 0.6x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) is...
Seeking Alpha • Aug 18

Science 37, Syapse team for faster patient enrollment in cancer trials

Science 37 (NASDAQ:SNCE) Syapse said they are collaborating to deploy proprietary real-world data intelligence and analytics to help identify suitable patients for oncology clinical trials, thus helping speed up the enrollment process. "By partnering with Syapse, we will have the ability to tap into advanced data-intelligence capabilities to make effective trial identification and recruitment a reality for patients and sponsors," said Science 37 Chief Medical Officer Jonathan Cotliar.
Seeking Alpha • Aug 11

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 press release (NASDAQ:SNCE): Q2 GAAP EPS of -$0.05 beats by $0.19. Revenue of $19.3M (+53.8% Y/Y) misses by $0.2M. Net bookings were $25.4M for the quarter ended June 30, 2022, compared to $44.1M for the same period in 2021. Adjusted EBITDA was -$16.5M for the quarter ended June 30, 2022, compared to -$5.4M in the same period in 2021.  Science 37 is providing revenue guidance of $76 million to $86 million vs. consensus of $92.24M and adjusted EBITDA guidance of $(65) million to $(69) million for the fiscal year ending December 31, 2022.
Analysis Article • May 13

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a sad week for Science 37 Holdings, Inc. ( NASDAQ:SNCE ), who've watched their investment drop 20% to US$3.03...
Analysis Article • Apr 11

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jan 02

Science 37: Pioneering Decentralized Clinical Trials

Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs. The Company is a leader in its niche DCT market worth over $60 billion.
Analysis Article • Nov 04

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

SNCEUS Life SciencesUS Market
7D0.3%-1.6%1.7%
1Y30.9%9.8%25.1%

Return vs Industry: SNCE exceeded the US Life Sciences industry which returned 9% over the past year.

Return vs Market: SNCE matched the US Market which returned 31% over the past year.

Price Volatility

Is SNCE's price volatile compared to industry and market?
SNCE volatility
SNCE Average Weekly Movement15.6%
Life Sciences Industry Average Movement8.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: SNCE's share price has been volatile over the past 3 months.

Volatility Over Time: SNCE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014460Dave Comanwww.science37.com

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company’s platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area.

Science 37 Holdings, Inc. Fundamentals Summary

How do Science 37 Holdings's earnings and revenue compare to its market cap?
SNCE fundamental statistics
Market capUS$34.67m
Earnings (TTM)-US$124.65m
Revenue (TTM)US$60.26m
0.6x
P/S Ratio
-0.3x
P/E Ratio

Is SNCE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNCE income statement (TTM)
RevenueUS$60.26m
Cost of RevenueUS$38.14m
Gross ProfitUS$22.12m
Other ExpensesUS$146.77m
Earnings-US$124.65m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-20.67
Gross Margin36.71%
Net Profit Margin-206.85%
Debt/Equity Ratio0%

How did SNCE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/11 00:45
End of Day Share Price 2024/03/11 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Science 37 Holdings, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric ColdwellBaird
Matthew HewittCraig-Hallum Capital Group LLC
Frank TakkinenLake Street Capital Markets, LLC